OBJECTIVES: Due to the increasing cost pressure, it is necessary to rely on cost-effective-therapies. Currently there are three monoclonal antibodies (Bevacizumab, Panitumumab, Cetuximab) in the treatment of colorectal cancer, which differ in their cost structure. Thus, this study aims to compare the costs of approved therapies from the hospital perspective. METHODS: The cost analysis includes all direct resources in the course of medication therapy. All relevant direct medical costs associated with the treatment were detected and quantified: drug costs of the antibodies, medical consumables, personnel costs and KRAS-testing. Furthermore, the number-needed-to-treat (NNT) for the three alternatives was calculated. Additionally, based on the total costs, a cost-effectiveness-depiction represents the additional costs of the overall-survival (OS) per month. RESULTS: The absolute benefit of the add-on-therapy leads to a longer progression-free-survival (PFS) in the treatment-group compared to the control-group. The relative superiority in PFS for Bevacizumab is 82.4%, 17.9% for Cetuximab and 20% for Panitumumab. Based on the PFS, the NNT for Bevacizumab accounts for 2 patients, 6 for Cetuximab and 5 for Panitumumab vs. the control-group. According to the frequency of the number of administrations, the total cost for Bevacizumab amounts to €2,442.87 per month, €3,693.89 for Cetuximab and €3,671.37 for Panitumumab. The savings of Bevacizumab vs. Cetuximab, based on the total cost, are €1,251.02 per month. The cost difference of Bevacizumab compared with Panitumumab amounts to €1,228.50 per month. Based on the indirect comparison trial (ITC), the monthly costs per OS for Bevacizumab amounts to €1,035.19 compared with Cetuximab (€1,611.55) and Panitumumab (€1,609.19). With regard to the overall treatment, the cost savings amounts to €7,581.58 for Bevacizumab compared to Cetuximab and for Panitumumab €8,719.54. CONCLUSIONS: The presented data of the cost-comparison-analysis for the approved antibodies therapy are able to demonstrate the possible potential savings through the therapy with Bevacizumab.